In February, UNC neurologist Hae Won Shin, MD, and neurosurgeon Eldad Hadar, MD, were the first in the state to implant the NeuroPace RNS System following the medical device’s recent FDA approval. In clinical trials, the NeuroPace system greatly reduced the number of seizures experienced by patients with severe epilepsy.
Dr. Harold Pillsbury performed the surgery to implant a newly FDA-approved device that enables wearers to have MRI scans when needed. This was not possible with earlier cochlear implant models.
Researchers from the UNC/NCSU Joint Department of Biomedical Engineering developed nanoparticles that could deliver cancer therapies in a safer and more effective way.
The probe, named UNC1215, will provide researchers with a powerful tool to investigate the function of malignant brain tumor (MBT) domain proteins in biology and disease.
New research led by Patrick F. Sullivan, MD, FRANZCP, a psychiatric geneticist at the University of North Carolina School of Medicine, points to an increased risk of autism spectrum disorders among individuals whose parents or siblings have been diagnosed with schizophrenia or bipolar disorder.
UNC researchers describe how exploiting the molecular mechanism behind acupuncture resulted in six-day pain relief in animal models. They call this new therapeutic approach PAPupuncture.
Clinical Trials, Innovation, Pain Management, Research, Treatment
CHAPEL HILL -- Scientists at the University of North Carolina at Chapel Hill have discovered key steps involved in regulating nerve growth and regeneration that may have implications for spinal cord research.
